Evidence map›Paper›PMID 33354688›Full record

ArticlemedRxiv : the preprint server for health sciences2020

Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality.

William Morgenlander, Stephanie Henson, Daniel Monaco, Athena Chen, Kirsten Littlefield, Evan M Bloch, Eric Fujimura, Ingo Ruczinski, Andrew R Crowley, Harini Natarajan and 19 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 4 institutions in 1 country.

William MorgenlanderInstitute for Cell Engineering, Division of Immunology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Stephanie HensonInstitute for Cell Engineering, Division of Immunology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Daniel MonacoInstitute for Cell Engineering, Division of Immunology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Athena ChenDepartment of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Kirsten LittlefieldW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Evan M BlochDivision of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Eric FujimuraDivision of Genetics, Department of Medicine, Howard Hughes Medical Institute, Brigham and Women's Hospital, Boston, MA, USA; Department of Genetics, Program in Virology, Harvard University Medical School, Boston, MA, USA.
Ingo RuczinskiDepartment of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Andrew R CrowleyDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.
Harini NatarajanDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.
Savannah E ButlerDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.
Joshua A WeinerThayer School of Engineering, Dartmouth College, Hanover, NH, USA.
Mamie Z LiDivision of Genetics, Department of Medicine, Howard Hughes Medical Institute, Brigham and Women's Hospital, Boston, MA, USA; Department of Genetics, Program in Virology, Harvard University Medical School, Boston, MA, USA.
Tania S BonnyDivision of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sarah E BennerDivision of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ashwin BalagopalDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
David SullivanW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Shmuel ShohamDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Thomas C QuinnDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Susan EshlemanDivision of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Arturo CasadevallW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Andrew D ReddDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Oliver LaeyendeckerDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Margaret E AckermanThayer School of Engineering, Dartmouth College, Hanover, NH, USA.
Andrew PekoszW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Stephen J ElledgeDivision of Genetics, Department of Medicine, Howard Hughes Medical Institute, Brigham and Women's Hospital, Boston, MA, USA; Department of Genetics, Program in Virology, Harvard University Medical School, Boston, MA, USA.
Matthew RobinsonDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Aaron A R TobianDivision of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
H Benjamin LarmanInstitute for Cell Engineering, Division of Immunology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins University · USDartmouth College · USBrigham and Women's Hospital · USNational Institutes of Health · US

Funding

LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
IMMUNOBIOLOGY OF MYELOID AND LYMPHOID CELLST32AI007363 · NIAID · DARTMOUTH COLLEGE · PI Claudia V Jakubzick · 1990 to 2026
$9.5M
Synergy of Host Defense Mechanisms in the LungR01HL059842 · NHLBI · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1997 to 2023
$7.4M
Biology of Fungal MelaninR01AI052733 · NIAID · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 2003 to 2019
$6.6M
Unlocking the Potential of HIV-Infected Deceased Donors for Organ TransplantationR01AI120938 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2016 to 2021
$4.3M
Development of Highly Multiplex Antigen Specificity AssaysU24AI118633 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ELLEDGE, STEPHEN J, LARMAN, HARRY BENJAMIN · 2015 to 2020
$2.4M
Penile Microbiome, Inflammation and HIV Susceptibility During Sexual Debut and Maturation Among Male AdolescentsR01AI128779 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2017 to 2020
$2.1M
Design and Analysis of Displayed PeptidomesR01GM136724 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI LARMAN, HARRY BENJAMIN, RUCZINSKI, INGO · 2020 to 2023
$1.9M
The Malaria Transfusion Risk (MATRix) StudyK23HL151826 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BLOCH, EVAN MARTIN · 2020 to 2024
$882k
LONGITUDINAL STUDY OF DEPRESSION IN LUNG CANCERR01NR005228 · NINR · UNIVERSITY OF SOUTH FLORIDA · PI WEITZNER, MICHAEL A · 1999 to 2002
$550k
A prospective evaluation of chronic B.microti infection in seroreactive blood donR21HL117140 · NHLBI · VITALANT · PI BLOCH, EVAN MARTIN · 2013 to 2014
$452k
NHLBI NIH HHS K23 HL151826NHLBI NIH HHS R01 HL059842NIAID NIH HHS HHSN272201400007CNIAID NIH HHS R01 AI052733NIAID NIH HHS R01 AI120938NIAID NIH HHS R01 AI128779NIAID NIH HHS T32 AI007363NIAID NIH HHS U24 AI118633NIAID NIH HHS UM1 AI068613NIGMS NIH HHS R01 GM136724NINR NIH HHS R01 NR005228
6 · The paper itself

Abstract

COVID-19 convalescent plasma, particularly plasma with high-titer SARS-CoV-2 (CoV2) antibodies, has been successfully used for treatment of COVID-19. The functionality of convalescent plasma varies greatly, but the association of antibody epitope specificities with plasma functionality remains uncharacterized. We assessed antibody functionality and reactivities to peptides across the CoV2 and the four endemic human coronavirus (HCoV) genomes in 126 COVID-19 convalescent plasma donations. We found strong correlation between plasma functionality and polyclonal antibody targeting of CoV2 spike protein peptides. Antibody reactivity to many HCoV spike peptides also displayed strong correlation with plasma functionality, including pan-coronavirus cross-reactive epitopes located in a conserved region of the fusion peptide. After accounting for antibody cross-reactivity, we identified an association between greater alphacoronavirus NL63 antibody responses and development of highly neutralizing antibodies to SARS-CoV-2. We also found that plasma preferentially reactive to the CoV2 receptor binding domain (RBD), versus the betacoronavirus HKU1 RBD, had higher neutralizing titer. Finally, we developed a two-peptide serosignature that identifies plasma donations with high anti-S titer but that suffer from low neutralizing activity. These results suggest that analysis of coronavirus antibody fine specificities may be useful for selecting therapeutic plasma with desired functionalities.

Identifiers

PMID33354688
PMCPMC7755150
OpenAlexW3112971914

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.